Cargando…
Exploiting the acquired vulnerability of cisplatin-resistant tumors with a hypoxia-amplifying DNA repair–inhibiting (HYDRI) nanomedicine
Various cancers treated with cisplatin almost invariably develop drug resistance that is frequently caused by substantial DNA repair. We searched for acquired vulnerabilities of cisplatin-resistant cancers to identify undiscovered therapy. We herein found that cisplatin resistance of cancer cells co...
Autores principales: | Chen, Jing, Wang, Xue, Yuan, Yuan, Chen, Haoting, Zhang, Lingpu, Xiao, Haihua, Chen, Jingqi, Zhao, Yongxiang, Chang, Jin, Guo, Weisheng, Liang, Xing-Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997498/ https://www.ncbi.nlm.nih.gov/pubmed/33771859 http://dx.doi.org/10.1126/sciadv.abc5267 |
Ejemplares similares
-
Bioimaging guided pharmaceutical evaluations of nanomedicines for clinical translations
por: Tuguntaev, Ruslan G., et al.
Publicado: (2022) -
Aberrant ROS Served as an Acquired Vulnerability of Cisplatin-Resistant Lung Cancer
por: Xin, Qian, et al.
Publicado: (2022) -
Targeting of Evolutionarily Acquired Cancer Cell Phenotype by Exploiting pHi-Metabolic Vulnerabilities
por: Ordway, Bryce, et al.
Publicado: (2020) -
Exploiting Phagocytic Checkpoints in Nanomedicine: Applications in Imaging and Combination Therapies
por: Landry, Madeleine R., et al.
Publicado: (2021) -
Exploiting Nanomedicine for Cancer Polychemotherapy: Recent Advances and Clinical Applications
por: Boggio, Elena, et al.
Publicado: (2023)